VOSOL
LOE ApproachingNDAOTICSOLUTION/DROPS
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOSOL is an otic solution approved in 1960 for topical treatment of ear conditions. The exact mechanism of action and therapeutic indication are not publicly detailed in available data, but the otic route and solution formulation suggest treatment of external or middle ear infections or inflammation. This is a legacy small-molecule product with established clinical utility in otolaryngology.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a contracting brand team and focus on defensive strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, VOSOL represents a consolidation or wind-down opportunity rather than a growth platform. Professionals joining this team should expect focus on efficiency, cost management, and defending market share against generics.
Brand ManagerField Sales Representative
Worked on VOSOL at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.